Biopsy

Beyond the interpretive problem, Aajonus identified a direct physical danger in the act of performing a biopsy. He described the biopsy process as involving multiple tissue plugs being taken from a site, and he argued that this mechanical puncturing of tissue that might otherwise be benign could itself cause cancer to develop. In one case he described, a patient had lumps that he believed were not tumors in any malignant sense, and he advised against the biopsy. The patient went ahead with it anyway, took one plug, and called Aajonus two days later saying the result came back benign. Aajonus's response in recounting this case was to note that by the time the biopsy is complete, with several plugs taken, the likelihood of inducing cancer in the disturbed tissue is significant. His phrasing was direct: "by the time they finish, you're likely to get cancer." The implication was that a site that was not cancerous before the procedure could become cancerous as a result of the procedure.

Aajonus explained repeatedly that cancer cells will always be found in lymphatic tissue because that is precisely where they operate. The lymph glands are responsible for dissolving dead cells and removing waste from the body. Cancer cells, in his framework, carry a dissolving fluid similar to what he described in viruses, a solvent capable of breaking down dead and hardened tissue. One cancer cell, when it dies, can release enough of this solvent to dissolve anywhere from one hundred to two hundred surrounding dead cells. The lymph glands are concentrated sites of this activity.

Medical thresholds for diagnosing treatable cancer were something Aajonus found absurd. He noted that the medical profession considers fifty cancer cells per million cells to constitute treatable cancer, and he regarded this figure as radical in its overreaction. His position was that at that concentration, the cancer cells represent a completely normal housekeeping function. He suggested that a figure of one hundred thousand to two hundred thousand cancer cells per million might indicate something worth paying attention to, and even then, he argued, the appropriate response would be natural rather than medical.

Aajonus described a situation in his own medical history in which, after chemotherapy, doctors diagnosed him with lymphoma and told him he needed to go back for a biopsy. His recorded response was immediate and unambiguous: "biopsy yourself," was the phrase he used. He refused entirely. This was not an impulsive reaction but a principled one grounded in his understanding of why lymph glands contain cancer cells and why a biopsy of those glands would inevitably return a positive result that he considered meaningless as evidence of disease.

Aajonus was particularly concerned about the chain of interventions that a biopsy result set in motion. In his observation, a positive biopsy result, especially one from lymphatic tissue, was routinely used to justify the removal of lymph nodes or lymph glands. He described a case involving his own mother, a nurse, who had been diagnosed with cancer via biopsy and was then recommended to have eleven lymph glands removed from around her breast in a lymphectomy. Aajonus's objection was anatomically specific: those eleven lymph glands were responsible for cleaning dead cells and toxins out of the breast area. Removing them would eliminate the body's local capacity to manage waste in that region. His question to her was direct and unanswered by her doctors: without those lymph glands, where would toxins inhaled or absorbed go? His answer was that they would migrate to other lymph gland clusters in the neck or underarm, those sites would be overwhelmed, and the result could be cancer developing in areas that previously had the capacity to remain clean.

He made the same argument in a different case involving a patient with a neck tumor. When he sent the patient to a surgeon, the surgeon's initial recommendation was to remove all the lymph glands in the neck because cancer was present. Aajonus challenged this directly, explaining to the chief of surgery at Kaiser that removing those lymph glands would eliminate the body's mechanism for cleaning that region, and that the cancer cells found there were evidence of the lymph system working rather than failing. His argument was: if you remove the lymph glands that are cleaning the area, where will the cancer go? His answer was the brain, lungs, or breast. He persuaded the surgeon to instead cut out only the tumor itself, leaving the lymph glands intact.

Aajonus also discussed biopsy in the context of the distinction between benign and malignant tumors. In his framework, a malignant tumor is one that has blood circulation, lymphatic circulation, and neurological circulation running through it. This makes it easier, not harder, to dissolve, because the circulatory access allows the body to transport nutrients and solvents to the tumor site. A benign tumor has none of this circulation; it is a solid mass with no internal blood supply, and the body must dissolve it from the outside inward, which is a much slower process.

The relevance to biopsy is that when a biopsy is performed on a malignant tumor, meaning one with active circulation and cancer cells, those cancer cells are actively secreting dissolving fluid as part of the normal dissolution process. Puncturing the tumor and extracting plugs of tissue disrupts this process, potentially spreading the dissolving fluid and the cells into surrounding tissue in ways the body had not organized. Aajonus implied that this mechanical disruption is part of how biopsies can convert a manageable tumor situation into a spreading cancer.

In a written exchange, a patient reported that a thyroid specialist had found a nodule measuring 1.35 centimeters on the thyroid, and that the specialist's position was that nodules over one centimeter require biopsy due to cancer risk. The specialist had also noted the thyroid was rock hard, consistent with Hashimoto's. Aajonus's written response framed the situation entirely within his dead-cell-accumulation model. He explained that when the lymphatic system can no longer dissolve all dead cells, the body stores them within itself, forming either fibroid tissue or tumors that may be benign or malignant. A hardened gland indicates that many dead cells have collected there as fibroid. Nodules are small benign tumors that form when the body cannot store dead cells as fibroid. He did not in the available text specifically respond to whether this patient should accept or refuse the biopsy, but his framing of the nodule as a benign tumor formed from dead cell accumulation rather than as a cancer risk indicator is consistent with his general position that biopsy in such circumstances would misread normal pathology.

It is worth distinguishing Aajonus's own use of tissue sampling from the medical biopsy he opposed. He described having small tissue samples taken from people with long histories of drug use, specifically from hard dry spots on the skin, in order to analyze for chemical residues. He also described having tissue samples taken from the throats of people with histories of taking specific drugs. These analyses were conducted to demonstrate that medications store in tissues. He also arranged tissue sampling from cadavers in the late 1980s through a forensic mortuary contact, paying for specific tests he wanted run, in order to analyze vaccine residues in stomach lining tissue. This was not diagnostic biopsy in the medical sense but investigative tissue chemistry analysis that he used to support his broader arguments about toxic accumulation.

He also paid for tumor analysis, noting that he spent eight thousand dollars having one tumor analyzed to identify its constituent chemicals. In cases he described, tumors came back with concentrations of heavy metals, kerosene, and minerals, often traceable to decades of supplement use. This kind of post-excision chemical analysis was something he found valuable precisely because it identified the actual stored toxins rather than making inferences from cell morphology.

Aajonus's position on biopsy can be summarized in his own framework terms. Cancer cells are not the problem; they are the solution. They will always be present in lymphatic tissue and at tumor sites because they are the body's dissolving agents for dead cell accumulation. A biopsy samples tissue that contains these cells by design, returns a result that medicine interprets as dangerous, and initiates a chain of interventions, lymph node removal, radiation, chemotherapy, that eliminate the body's capacity to do the cleanup work the cancer cells were performing. The biopsy procedure itself carries the additional risk of inducing cancerous activity in tissue that was not previously in that state, through the mechanical trauma of plug extraction. His personal refusal of a recommended biopsy when diagnosed with lymphoma, and his consistent advice to patients to avoid the procedure, were both grounded in this integrated framework rather than in blanket rejection of medical procedures.